Lupin is currently trading at Rs. 750.90, up by 12.55 points or 1.70% from its previous closing of Rs. 738.35 on the BSE.
The scrip opened at Rs. 744.00 and has touched a high and low of Rs. 757.05 and Rs. 735.60 respectively. So far 26755 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 2 has touched a 52 week high of Rs. 986.00 on 10-Sep-2018 and a 52 week low of Rs. 697.30 on 19-Jun-2019.
Last one week high and low of the scrip stood at Rs. 757.05 and Rs. 711.60 respectively. The current market cap of the company is Rs. 34117.26 crore.
The promoters holding in the company stood at 46.96%, while Institutions and Non-Institutions held 38.66% and 14.38% respectively.
Lupin’s American subsidiary — Lupin Pharmaceuticals Inc. is recalling 39,216 bottles of Lisinopril and Hydrochlorothiazide tablets USP, 10 mg/12.5 mg, 100 tablet bottle manufactured at its Pithampur facility from the US market. The reason for the recall is presence of foreign substance; product complaints received related to brownish/blackish stains on the tablets and brownish/blackish powder observed inside the bottles. The tablets are used for treatment of hypertension.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.